Mantara Health

Mantara Health Knowledge is the best medicine ™

🧬 New research adds to the growing evidence for Pharmacogenomic (PGx) testing in cardiovascular care.A recent study foun...
09/06/2026

🧬 New research adds to the growing evidence for Pharmacogenomic (PGx) testing in cardiovascular care.

A recent study found that genome-guided statin prescribing can be cost-effective, helping improve patient outcomes while reducing long-term healthcare costs. 💊

Read the paper: Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia

Want to learn more about PGx testing? Visit Mantara

Found this interesting? Tag someone who might want to learn more about the future of personalised medicine. 👇

02/06/2026

Why did Mantara start? 🧬

For Dr it came from seeing too many patients experience side effects and ineffective treatment when a more personalised approach could help.

In this video, Mark shares why he founded Mantara and how Pharmacogenomic (PGx) testing is becoming more accessible than ever before.

Learn more: mantara.co

Why do so many people stop antidepressants early?A recent study of 5,808 patients found that genetic variations in CYP2C...
27/05/2026

Why do so many people stop antidepressants early?

A recent study of 5,808 patients found that genetic variations in CYP2C19 and CYP2D6 were linked to significantly higher antidepressant discontinuation rates - particularly with medications including escitalopram, sertraline and venlafaxine.

The findings highlight the growing role of Pharmacogenomic (PGx) testing in helping clinicians better understand how an individual may process certain medications before prescribing - helping reduce trial and error and improve patient outcomes.

🔗 Read the study here: https://www.nature.com/articles/s41397-026-00416-2 

Follow for more updates and insights on PGx and personalised medicine.

A paper just published in npj Digital Medicine describes an AI system that can generate CPIC-style pharmacogenomic presc...
19/05/2026

A paper just published in npj Digital Medicine describes an AI system that can generate CPIC-style pharmacogenomic prescribing recommendations automatically, at scale, from published evidence.

It’s a significant development and it points to something already true: the science is moving faster than implementation. The volume of actionable PGx guidance is growing. The gap between what genetics can tell us and what prescribers are acting on remains wide.

The limiting factor was never the science. Getting the right genetic information into the right hands at the right moment is the challenge that still needs solving.

Swipe to see what this shift means for your patients today.

DM us or email [email protected]

Only around 1 in 3 people reach remission on their first antidepressant. For patients who’ve already tried two or more, ...
19/05/2026

Only around 1 in 3 people reach remission on their first antidepressant. For patients who’ve already tried two or more, the question worth asking is whether their genetics have ever been considered.

A new study published in The Pharmacogenomics Journal targeted PGx testing specifically at patients on psychiatric polypharmacy. 30% had an actionable gene-drug interaction - higher than general population studies typically find.

The patients most likely to be struggling were the most likely to carry a relevant variant.CPIC guidelines for antidepressants and CYP2D6/CYP2C19 are Grade A. The guidance exists.

Swipe to see what it means in practice.DM us or email [email protected] to find out how Mantara fits your service.

Two days at and some brilliant conversations with pharmacists, prescribers, and medicines optimisation leads about Phar...
13/05/2026

Two days at and some brilliant conversations with pharmacists, prescribers, and medicines optimisation leads about Pharmacogenomics. It’s clear the appetite for change is there and we’re excited about what’s coming.

Interested in PGx testing for your practice? DM us.





05/05/2026

Most people assume medication will just “work.”

In reality, it’s closer to this:

💊 1 in 3 patients get the intended effect
💊 1 in 3 need dose adjustments
💊 1 in 3 risk side effects or toxicity

Your genetics play a huge role in how your body responds.

That’s why understanding your genetic profile matters - it helps your doctor prescribe the right drug, at the right dose, from the start.

Three significant PGx resources have been published in the UK in the last three months.The RDTC set out how to embed PGx...
05/05/2026

Three significant PGx resources have been published in the UK in the last three months.

The RDTC set out how to embed PGx into NHS medicines governance. The UKCPA launched a free point-of-care handbook for pharmacists and GPs. And this week, the Royal Pharmaceutical Society published a new resource mapping pharmacogenomics directly to the Competency Framework for All Prescribers.

As Prof. William Newman put it at the RPS launch: "Pharmacogenomics is rapidly becoming part of routine NHS practice."

Clinicians have always wanted to prescribe well. The tools to do that with genomic precision are now arriving. At Mantara, we provide the testing that makes that possible today.

🔗 RPS resource: rpharms.com
🔗 UKCPA Handbook: pharmacogenomics-handbook.ukclinicalpharmacy.org

Nearly half of older people in England are now taking five or more medications simultaneously.Each drug is prescribed fo...
30/04/2026

Nearly half of older people in England are now taking five or more medications simultaneously.

Each drug is prescribed for good clinical reasons. But each one is also processed by the body and how that processing works is significantly influenced by genetics.

When multiple drugs are competing for the same metabolic pathways, undetected genetic variants don't just affect one medication.

They affect all of them at once.

Polypharmacy is associated with a 60% increased risk of mortality over five years in adults aged 75 and over. Genetics doesn't explain all of that. But it explains more than most prescribing decisions currently account for.

A pre-emptive PGx test, done once, on file permanently, is one of the most practical tools available for making polypharmacy safer.

🔗 Polypharmacy outcomes study: pmc.ncbi.nlm.nih.gov/articles/PMC11790100

Tricyclic antidepressants are still widely prescribed across UK practice - for depression, neuropathic pain, migraine, a...
28/04/2026

Tricyclic antidepressants are still widely prescribed across UK practice - for depression, neuropathic pain, migraine, and anxiety. And they have a narrow therapeutic window that makes getting the dose right genuinely consequential.

Two genes - CYP2D6 and CYP2C19 - significantly affect how TCAs are processed. For tertiary amines like clomipramine, doxepin, and imipramine, both genes are active simultaneously.

Poor metabolisers of either can accumulate drug levels high enough to increase the risk of serious side effects including cardiac arrhythmia.

CPIC recommends avoiding TCAs altogether in CYP2D6 poor and ultra-rapid metabolisers where alternatives exist, and a 50% dose reduction for CYP2C19 poor metabolisers with therapeutic drug monitoring.

It's not coincidental that the UKCPA Handbook of Pharmacogenomics chose these drugs as its opening monographs. This is where the clinical need is.

🔗 CPIC TCA guideline: cpicpgx.org/guidelines

🔗 UKCPA Handbook: pharmacogenomics-handbook.ukclinicalpharmacy.org

Address

London

Website

Alerts

Be the first to know and let us send you an email when Mantara Health posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Mantara Health:

Shortcuts

Featured

Share

Category